NCT01730781Recruiting
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Characterization of CB1 Receptors Using [11-C]OMAR
Source: ClinicalTrials.gov · Last updated 27 Apr 2026
Brief summary (registry, in English)
The aim of the present study is to assess the availability of cannabinoid receptors (CB1R) in the human brain. CB1R are present in everyone's brain, regardless of whether or not someone has used cannabis. The investigators will image brain cannabinoid receptors using Positron Emission Tomography (PET) imaging and the radioligand OMAR, in healthy individuals and several conditions including 1) cannabis use disorders, 2) psychotic disorders, 3) prodrome of psychotic illness and 4) individuals with a family history of alcoholism, 5) Post-Traumatic Stress Disorder 6) Opioid Use Disorder using the PET imaging agent or radiotracer, \[11C\]OMAR. This will allow us to characterize the number and distribution of CB1R in these conditions. It is likely that the list of conditions will be expanded after the collection of pilot data and as new data on cannabinoids receptor function and psychiatric disorders becomes available. Those in the cannabis us disorder arm of the study will have a PET scan on at least three occasions: once while smoking as usual, once after 48-hours of abstinence from cannabis, and a final time after 4 weeks of abstinence. Additional scans may be conducted within the 4 weeks and the last scan may be conducted well beyond 4 weeks. Similarly, while most schizophrenia patients may get scanned just once, a subgroup of patients may get scanned more than once. For example to tease out the effects of medications, unmedicated patients may get scanned while unmedicated and again after treatment with antipsychotic medications. Similarly prodromes may get scanned while in the prodromal stage off medications, on medications and after conversion to schizophrenia.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 14 Jun 2012
- Start date
- Jul 2010
- Primary completion date
- Dec 2026
- Lead sponsor
- Yale University
- Diseases
- Schizophrenia
- NCT number
- NCT01730781
What you commit to
- Study type: Observational
- Planned participants: 100
- From Jul 2010 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have had exposure to ionizing radiation that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits
Other illness
- Current neuro-psychiatric illness (including cannabis dependence) or severe systemic disease. Cannabis use disorder is permitted in the cannabis dependent group. Schizophrenia and schizoaffective disorder is permitted in the schizophrenia group. Psychotic symptoms are permitted in the prodromal group. Post-Traumatic Stress Disorder is permitted in the PTSD group and Opioid Use Disorder is permitted in the OUD group.
- Presence of ferromagnetic metal in the body or heart pacemaker
Other
- Are claustrophobic
Who the study is looking for
- Males ages 18-55
- For cannabis users:
- Willing to abstain from cannabis use for four weeks
- For schizophrenia:
- Meets DSM-IV-TR criteria for schizophrenia or schizoaffective disorder
- For prodrome for psychotic illness:
- Meets SIPS criteria for prodromal syndrome
- For family history positive:
- First degree relative with alcoholism
- For Post-Traumatic Stress Disorder
- Meets DSM-IV-TR criteria for PTSD
- For OUD
- Meets DSM-IV-TR criteria for Opioid Use Disorder
Age in the registry: 18 years to 55 years · Sex: Male · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Connecticut Mental Health Center, Clinical Neuroscience Research Unit Coordinator of this site? Confirm its status | New Haven | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.